ArticleEuropean journal of clinical pharmacology2012
Feasibility of pharmacy-initiated pharmacogenetic screening for CYP2D6 and CYP2C19.
Article in European journal of clinical pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 34 citations in OpenAlex.
- Implementing pharmacogenetic testing in community pharmacy practice: a scoping review.Frontiers in pharmacology · 2025Pooled it
- Pharmacogenetic interventions to improve outcomes in patients with multimorbidity or prescribed polypharmacy: a systematic review.The pharmacogenomics journal · 2022Pooled it
- Public perceptions of pharmacogenomic services in Ireland - Are people with chronic disease more likely to want service availability than those without? A questionnaire study.Exploratory research in clinical and social pharmacy · 2022Article
- A Theory-Informed Systematic Review of Barriers and Enablers to Implementing Multi-Drug Pharmacogenomic Testing.Journal of personalized medicine · 2022Review
- The feasibility and potential of pharmacogenetics to reduce adverse drug events in nursing home residents.Journal of the American Geriatrics Society · 2022Article
- The usefulness of Olanzapine plasma concentrations in monitoring treatment efficacy and metabolic disturbances in first-episode psychosis.Psychopharmacology · 2021Article
- Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting.Pharmacogenomics and personalized medicine · 2021Article
- Antipsychotic Polypharmacy.Focus (American Psychiatric Publishing) · 2020Article
- Article
- The Three Ps: Psychiatry, Pharmacy, and Pharmacogenomics, a Brief Report From New Zealand.Frontiers in psychiatry · 2019Article
- Relationship between cytochrome P450 polymorphisms and prescribed medication in elderly haemodialysis patients.SpringerPlus · 2016Article
- Pharmacogenomics in diverse practice settings: implementation beyond major metropolitan areas.Pharmacogenomics · 2015Article
- Comparison of delivery strategies for pharmacogenetic testing services.Pharmacogenetics and genomics · 2014Review
- Clinical delivery of pharmacogenetic testing services: a proposed partnership between genetic counselors and pharmacists.Pharmacogenomics · 2013Article
- Primary care physicians' knowledge of and experience with pharmacogenetic testing.Clinical genetics · 2012Article
- Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.Pharmacy practiceArticle
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeOur purpose was to investigate the feasibility of pharmacy-initiated pharmacogenetic (PGt) screening in primary care with respect to patient willingness to participate, quality of DNA collection with saliva kits, genotyping, and dispensing data retrieved from the pharmacy.
methodsPolypharmacy patients aged >60 years who used at least one drug with Anatomical Therapeutic Chemical (ATC) code N06AA01-N06AX19 (antidepressants), A02BC01-A02BC05 (proton-pump inhibitors), N05AA01-N05AH04 (antipsychotics), or C07AB02 (metoprolol) in the preceding 2 years were randomly selected. DNA was collected with saliva kits and genotyped for CYP2D6 and CYP2C19 with the AmpliChip. Pharmacy dispensing records were retrieved and screened for drugs interacting with the patient's CYP2D6 and CYP2C19 genotype by using the evidence-based PGt guidelines from the Dutch Pharmacogenetics Working Group.
resultsOut of the 93 invited patients, 54 (58.1%) provided informed consent. Nine saliva samples (16.7%) contained too little DNA. Call rates for CYP2D6 and CYP2C19 were 93.3% and 100%, respectively. Frequencies of genotype-predicted phenotype were 2.4%, 38.1%, 54.8%, and 4.8% for CYP2D6 poor metabolizers (PM), intermediate metabolizers (IM), extensive metabolizers (EM), and ultrarapid metabolizers (UM) respectively. For CYP2C19 genotype-predicted phenotype, frequencies were 2.2%, 15.6%, and 82.2% for PM, IM, and EM, respectively.
conclusionsThis study shows that pharmacy-initiated PGt screening is feasible for a primary care setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.